RLVS Δ<i>capB</i>/Yp F1-V single vector platform vaccine expressing <i>Yersinia pestis</i> F1 and LcrV antigens provides complete protection against lethal respiratory challenge with virulent plague bacilli.

ABSTRACT: Yersinia pestis, the causative agent of plague, is classified as a Tier I Select Agent of bioterrorism and is among a few pathogens of high concern as a potential cause of a future pandemic. Currently, there is no licensed vaccine against plague. Previously, we developed a live attenuated vaccine candidate, rLVS ΔcapB/Yp F1-V, that utilizes a highly attenuated capB mutant of Francisella tularensis Live Vaccine Strain as a vector to express a fusion protein of Y. pestis F1 and LcrV antigens. We showed that homologous prime-boost vaccination with this vaccine provided potent protection in mice against lethal respiratory challenge with virulent Y. pestis. Here, we report on the immunogenicity and efficacy of rLVS ΔcapB/Yp F1-V and additional LV

SUBMITTER: Jia Q 

PROVIDER: S-EPMC12118393 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature